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Abstract
Background: The purpose of this study was to identify differences in clinical corneal findings after standard and
accelerated epithelial off cross-linking (CXL) during a long-term follow-up.
Methods: Two hundred forty-one patients (184 male) were included in this monocentric, retrospective, non-randomized
and unmasked study. One hundred forty-eight eyes were treated with the accelerated protocol and 138 with the
standard protocol with epithelial off CXL, if diagnosed with keratoconus and a progression in Kmax of more than one
dioptre during the preceding 6 months, plus a minimal pachymetry measurement of 400 μm in keratometry (Pentacam,
Oculus GmbH, Wetzlar, Germany). Exclusion criteria were previous surgery, other corneal conditions or age above
50 years. Follow-up time was 36 months with clinical examination and keratometry at every visit. Outcome measures
were the observed rate of corneal changes, differences between treatment groups and correlation with keratometry
measurements.
Results: In patients with accelerated CXL, significantly more clear corneas were seen at three (p = 0.015) and six (p = 0.002)
months after surgery than following the standard protocol. The rate of clear corneas dropped from 52.2% pre-operation
(OP) to a minimum of 19.3% after 6 months in the standard protocol group compared with 50.7% clear corneas pre-OP
and a minimum of 40.8% in the accelerated group. In the standard protocol group, more striae were found 3 months
after intervention than in the accelerated group (p = 0.05).
Conclusions: In patients with accelerated CXL, fewer morphological corneal changes were observed than after
conventional CXL. However, rarely, corneal changes persisted for a long time.
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Background
Keratoconus is a mostly bilateral non-inflammatory cor-
neal disease that alters stability and refractive power
because of progressive thinning and protrusion, mostly
in the inferior part of the cornea [1]. More men than
women, predominantly in adolescence, are affected [2].
As this is a progressive disease, close monitoring is
essential to detect any subtle change in measurement
values. In addition to clinical examination, monitoring is
achieved in most cases by using a digital keratometric
system that measures the anterior and posterior corneal
curvature for the detection of early changes [3–5]. A
recent study has shown that the number of corneal
transplantations can be reduced significantly by the use
of a cornea-preserving therapeutically option named cor-
neal cross-linking (CXL) [6].
CXL in patients with keratoconus was first performed
in a prospective non-randomized clinical trial in 2003
and aimed at halting the progression of the disease by
strengthening the cornea [7]. Success had previously
been shown in animal eyes [8]. In this first study in
patients, treatment was performed with riboflavin drops
and ultraviolet-A (UVA) irradiation (370 nm, 3 mW/
cm2 for 30 min), i.e. with the so-called “Dresden
protocol”.
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Meanwhile, an accelerated protocol was developed,
whereby the radiation power was increased, but the
duration of the treatment was reduced. This accelerated
treatment was recently compared, in humans, with the
standard Dresden protocol and proved to be as effective
for corneal flattening as the original Dresden protocol
[9]. This method is used nowadays routinely in clinics
worldwide. Protocols in which the epithelium is not
removed, some of them also involving the use of Ionto-
phoresis, have proved to be inferior [10].
Despite CXL being a quicker and less invasive therapy
than perforating keratoplasty, significant side effects can
arise with regard to this treatment strategy [11]. Usually,
in most patients, corneal haze is visible after therapy. Fur-
thermore, some patients suffer from sterile inflammation
or scaring that persists and can decrease visual acuity.
The aim of this study has been to analyse the long-
term clinical changes in human corneas after CXL car-
ried out because of progressive keratoconus in two
observational groups treated at Munich’s University Eye
Hospital. One group was treated according to the ori-
ginal Dresden protocol, whereas the second group was
treated according to the accelerated protocol. Clinical
findings were correlated with various measurements.
Clinical and measurement data were retrieved from the
Smart Eye Database, which incorporates real-life data
from more than 350,000 patients [12].
Methods
Patients
Patients were referred from ophthalmological practices,
mostly located in the state of Bavaria, Germany, to the
University Eye Hospital Munich, because of confirmed
or suspected keratoconus, for further evaluation or treat-
ment. Patients were informed about CXL therapy and
gave consent to the procedure. Approval for this study
was provided by the Institutional Review Board (IRB) of
the University Eye Hospital of Munich and adhered to
the tenets of the Declaration of Helsinki. Due to the
retrospective nature of this study, the IRB ruled, that no
consent for participation was necessary. All patients in-
cluded in this study had progressive keratoconus at least
in one eye, defined as an increase in the maximum kera-
tometry (Kmax) value in Pentacam (Oculus GmbH,
Wetzlar, Germany) measurements of more than one
dioptre in the preceding 6 months. Patients were told
not to wear contact lenses 5 days prior to the measure-
ment. A minimal corneal thickness of 400 μm or more
and a clear cornea with no scarring was required for
treatment inclusion. Exclusion criteria included previous
ocular trauma or surgery, corneal disease (other than
keratoconus) or systemic disease that might affect the
cornea, stable conditions of keratoconus and a study
subject age of more than 50 years.
Surgical treatment
From 2009 to 2013, all patients received treatment
according to the Dresden protocol via an UVX-1000 de-
vice (IROC; Switzerland, 3 mW, 30 min). All Patients
recruited from 2013 to 2016 were treated according to
an accelerated protocol by using an UVX-2000 device
(IROC; Switzerland, 9 mW, 10 min). In this retrospect-
ive analysis, assignment of patients to treatment proto-
cols was only done by the date of CXL and the current
standard of care at that time (Until 2013: Dresden proto-
col, from 2013: accelerated protocol). No further consid-
erations were made. In all cases, CXL was performed as
an outpatient procedure under topical anaesthesia by
using the “epithelial-off” technique. After epithelial de-
bridement, riboflavin drops were instilled every 5 min
for 30 min in the Dresden protocol group (Medio Cross
isotone, Peschke GmbH, Waldshut-Tiengen, Germany)
and every 2 min for 10 min in the accelerated group
(VibeX rapid, Avedro Inc., Waltham, MA, USA). Imme-
diately afterwards, light irradiation was started in the
Dresden protocol group for 30 min and in the acceler-
ated group for 10 min. The source was mounted at 5 cm
distance from the corneal apex to cover the whole cor-
nea with light irradiation. To reduce pain and irritation,
a soft bandage contact lens was inserted after surgery
until the epithelium healed. All surgical interventions
were uneventful. Patients were treated postoperatively
with preservative-free Levofloxacin antibiotic eye drops
and dexamethasone eye drops, both 4 times daily. Lubri-
cating eye drops were also prescribed. Treatment with
the antibiotic drops was stopped on contact lens re-
moval after four to 5 days. Dexamethasone eye drops
were reduced by one drop per week.
Follow-up period
On every follow-up examination (1–3, 6, 9, 12, 24 and
36 months after the procedure; except for the first post-
operative (OP) day), a Pentacam (Oculus, Wetzlar,
Germany) examination was undertaken by using the
same device. Patients were instructed not to wear con-
tact lenses (if applicable) 5 days prior to every follow-up
examination, in order to reduce effects of corneal warp-
age. As not all patients attended at the same time inter-
vals, the incidence of findings in the intervals 0–3, 3–6,
6–9, 9–12, 12–24 and 24–36 months were assessed. For
every clinical examination, the corresponding measure-
ments (closest to examination date) from the Pentacam
were included. In cases of differences between the
Pentacam measurement and clinic dates, the values were
adjusted by linear interpolation. A clinical examination
that included an assessment of corneal findings (haze,
striae, infiltrates, opacification, scar, oedema and epithe-
lial defect) was performed. Uncorrected and corrected
visual acuity was tested.
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Data analysis
Data were exported from the Smart Eye Database, which
includes all patient data from the electronic health rec-
ord and measurement values from the Pentacam for
every examination. Statistical analysis was performed by
using R software (https://www.r-project.org/, The R pro-
ject for Statistical Computing Version 3.2.2). Based on
the changes of incidences of fixed corneal findings
between the pre-OP and post-OP control points, the
exact McNemar test was used to detect significant dif-
ferences within the progress of clinical findings in both
groups. The exact McNemar Test was applied to the 2 ×
2-matrix consisting of the incidences for finding/finding,
finding/no finding, no finding/finding and no finding/no
finding at the pe-OP/post-OP-control-point for every
finding and every post-OP-control-point. In particular,
relationships between clinical findings and Pentacam meas-
urement values were established by using the Mann-
Whitney U-test.
Moreover, differences between the treatment protocols
were determined by considering the number of inci-
dences for fixed findings and control-points and by
applying the exact Fisher test to the related 2 × 2-matrix.
To obtain an additional value for dissimilarity beside the
results of the McNemar test and the Fisher test, odds
ratio values were established. An odds ratio of <1 means
a change from “finding occurs” to “finding does not
occur”, whereas an odds ratio of >1 implies the opposite
conclusion. All results were considered statistically sig-
nificant at p < 0.05.
Results
Patients and pre-treatment measurements
For this study, we included 241 patients (184 male
patients, average age 27.9 years), with 286 treated eyes.
Before treatment, Kmax was 54.25 D and Kmean front
(Kmf) was 46.34 D in the accelerated treatment group,
whereas in the Dresden protocol treatment group, Kmax
was 55.53 D and Kmf 47.76 D. The average pachymetry
was 467.62 μm (accelerated) or 457.75 μm (Dresden
protocol) pre-operatively. Table 1 shows the baseline
data of both groups. A normal distribution of pre-OP
Pentacam measurements was seen according to the
Anderson-Darling test.
Corneal findings during treatment
The course of corneal findings during therapy is shown
in Fig. 1 for the conventional Dresden protocol and Fig. 2
for the accelerated treatment. Before treatment, 52.2%
(Dresden protocol) or 50.7% (accelerated) of corneas
were clear and 43.5% (Dresden) or 46.6% (accelerated)
showed striae. The rate of clear corneas dropped during
treatment to a minimum of 19.3% after 6 months (Dres-
den) and to 40.8% after 12 months (accelerated). For
striae, the peak was at 67% after 6 months (Dresden)
and dropped to 55.7% after 36 months. In the acceler-
ated protocol, the peak of striae findings also occurred
after 36 months, but at a value of 52.4% with no inter-
mittent rise. Haze peaked in both protocols after 3
months at 70.5% (Dresden) and at 46.9% (accelerated).
The number of patients with opacifications peaked at
16.5% (accelerated) after 6 months, whereas in the
Dresden protocol, it peaked at 12.8% after 3 months. In
each group, two patients exhibited infiltrates. A scar
developed in eight (Dresden) and four (accelerated)
patients. We observed eight (Dresden) and two (acceler-
ated) patients with a persisting epithelial defect, only
after 3 months. The rate of oedema peaked in both
groups after 3 months, at 16.3% in the Dresden protocol
and at 3.8% in the accelerated group.
Correlation between clinical findings and Pentacam
measurements
All patients underwent Pentacam examinations at every
clinical visit. Table 2 shows the changes of corneal mea-
surements during therapy. The pre-OP measurements
revealed no statistically significant difference between
the two groups for Kmax but differences for Kmf and
pachymetry were significantly different. To assess signifi-
cant differences in corneal measurement values in
Pentacam examinations between patients with certain
findings, the Mann-Whitney U-test was performed.
Subsequently, data were compared with the values of a
clear cornea. Significant differences between clear cor-
neas and those with striae were seen when comparing
Kmax and partly Kmf and pachymetry, but to a greater
extent in the accelerated group (Table 4) than in the
Dresden protocol group (Table 3).
Table 1 Patient demographics
Items: Accelerated: Dresden protocol:
Number of patients
(male)
131 (98) 110 (86)
Eyes (male) 148 (110) 138 (109)
Average age
(male/female)
28.7+/−11.6
(27.6/31.9)
27.0+/−9.4
(25.7/ 31.9)
Right eyes (m/f) 68 (45/23) 76 (56/20)
Kmax pre-OP (mean,
sd, median)
54.3, 5.6, 53.8 55.5, 5.6, 55.4
Pachmetry pre-OP
(mean, sd, median)
467.6, 37.0, 466.5 457.6, 31.6, 460.9
KMF pre-OP (mean,
sd, median)
46.3, 3.5, 45.9 47.8, 3.4, 47.1
Visual acuity pre-OP
(logmar)
(mean, sd, median)
cc: 0.34, 0.24, 0.3
sc: 0.47, 0.33, 0.4
cc: 0.37, 0.28, 0.35
sc: 0.55, 0.37, 0.49
Patient demographics and characteristics. Kmax Maximal K value as measured
in keratometry, Kmf average keratometry reading of front cornea, cc cum
correctione (with best correction), sc sine correctione (without any correction)
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Predictions and comparison
To determine the likelihood that certain findings chan-
ged in the cornea, an analysis with the McNemar test
was performed. For the Dresden protocol, significant dif-
ferences were found concerning the appearance of cor-
neal striae and clarity between pre-surgery corneal
findings and during follow-up. The odds ratio for clear
corneas was 0.273 after 3 months and 0.152 after 6
months following therapy with the Dresden protocol.
For the accelerated protocol, no significant results were
obtained. For striae, significantly increased odds ratios
were measured in the Dresden protocol treatment
group: 4.0 after 6 months and 2.0 after 2 years.
To compare the two treatment protocols for the likeli-
hood of having a clear cornea and of finding haze or
striae, an exact Fisher test was performed. For clarity, a
significant odds ratio (0.417/0.232) was observed at three
and 6 months after treatment. This meant that a clear
cornea was more likely to be observed in the accelerated
group than in the standard group. In contrast, we mea-
sured a significant odds ratio after 3 months (2.073) for
striae, and hence striae were more likely to be seen in
the Dresden protocol group.
Discussion
In this study, we investigated and compared changes in
corneal clinical findings of keratoconus patients after
CXL with the established Dresden protocol and with the
accelerated protocol in 286 eyes retrospectively for 3
years following treatment.
During the last few years, several randomized clinical
trials have been conducted by using CXL [13–16]. All
have shown that keratoconus progression can be halted
and, in some cases, keratometry measurements and vis-
ual acuity can be improved. However, some controversy
regarding the recent Food and Drug Administration
Fig. 1 Conventional Dresden protocol: corneal characteristics and their extent during therapy
Fig. 2 Accelerated treatment protocol: corneal characteristics and their extent during therapy
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(FDA) approval exists [17]. CXL has also proved to be
successfully over time, as a long-term stabilization of the
cornea has been observed over 10 years [18]. The accel-
erated CXL treatment is known to be as effective as the
standard Dresden protocol [19–23]. The first experimen-
tal study was performed in 2011 in Switzerland. In total,
72 porcine eyes were randomly assigned to three differ-
ent treatment groups. Various CXL illumination inten-
sities were used: at 10 mW/cm2 for 9 min and at 3 mW/
cm2 for 30 min with a constant energy dose of 5.4 J/cm2
and a control with no radiation [24]. This investigation
revealed that rapid UV CXL treatment can be regarded
as equivalent to the standard procedure in terms of the
increase in corneal stiffness. However, another study of
porcine eyes showed that both the standard and the ac-
celerated protocols increased corneal enzymatic resist-
ance, although the amount of CXL might be less when
accelerated CXL is used [25].
As is known from previous studies, corneal CXL induces
morphological or inflammatory changes to the cornea, such
as haze, but these are resolved mostly after a few months
[26, 27]. In addition to clinical changes, other transforma-
tions are associated with CXL, such as keratocyte apoptosis
and thermomechanical behavioural alterations [28, 29].
Table 3 Corneal measurements following the Dresden protocol
Finding pre-OP 3 M 6 M 9 M 12 M 24 M 36 M
Kmax [D] clear 53.2 54.6 52.5 53.9 52.8 54.1 53.1
Striae 56.8 57 54.9 54.5 56.5 55.1 54.8
p Striae-clear 0* 0.06 0.73 0.64 0.15 0.35 0.01*
Haze – 54.9 56.1 52.3 53.2 53.8 50.1
p Haze-clear – 0.29 0.43 0.55 0.92 0.78 0.52
Kmf [D] clear 46.4 47.2 46.1 47.6 47.8 47.3 46.8
Striae 47.9 48.2 46.9 46.5 46.6 46.9 46.9
p Striae-clear 0.01* 0.14 0.93 0.49 0.59 0.73 0.13
Haze – 47.5 48.2 44.8 45 46.9 45.6
p Haze-clear – 0.49 0.58 0.4 0.56 0.95 0.73
Pachymetry [μm] clear 464.4 454 454 449.5 453 443 459.5
Striae 453 446.3 439.1 456 450 455 449
p Striae-clear 0.36 0.25 0.62 0.85 0.84 0.05* 0.49
Haze – 448 456.6 457 481 452 439
p Haze-clear – 0.5 0.65 0.92 0.44 0.38 0.66
Incidences [number of eyes] clear 72 37 17 18 17 50 34
Striae 60 67 59 38 31 52 45
Haze 0 91 16 6 1 7 1
Eyes 138 129 88 58 53 94 81
Corneal measurements (Dresden protocol, median) obtained during follow-up and concerning corneal findings and incidences. M months, Kmax maximum K read-
ing in keratometry measurement, D dioptres, Kmf average keratometry reading of front cornea), *=statistical significant difference
Table 2 Corneal measurements during follow-up period
pre-OP 3 M 6 M 9 M 12 M 24 M 36 M
Kmax (Dresden) [D] 55.53 55.85 55.32 55.01 55.28 55.43 55.41
Kmax (Accelerated) [D] 54.25 55.34 54.56 54.48 55.33 55.14 52.99
p-value 0.06
KMF (Dresden) [D] 47.76 47.96 47.78 47.41 47.41 48.05 47.94
KMF (Accelerated) [D] 46.34 47.06 46.70 46.66 47.08 47.41 45.80
p-value <0.01*
Pachymetry (Dresden) [μm] 457.75 444.92 441.51 445.15 452.18 446.81 443.65
Pachymetry (Acclerated) [μm] 467.62 460.38 455.32 466.17 467.48 462.07 448.38
p-value 0.014*
Corneal measurements during follow-up. M months, Kmax Maximal K value as measured in keratometry, Kmf average keratometry reading of front cornea. *=statistical
significant difference
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Long-term data exists showing corneal CXL to be a safe
procedure but, rarely, complications can arise [11, 18].
Most studies so far have focused on measurement data
from corneal diagnostics, such as Pentacam or Orbscan
examinations [30], in which a differentiation of findings
affecting densitometry cannot be made because of the way
in which the measurements have been taken. To our
knowledge, this is the first study that compares detailed
clinical findings of the two protocols over a long period
(36 months) in a large cohort.
On first impression (Figs. 1 and 2), the accelerated
protocol seems to have fewer effects on clinical findings
than the Dresden protocol. Before treatment, a pre-
operative haze was noted in three eyes. The average
Kmax value of these eyes was 51.2 D before treatment.
The two affected patients were lost to follow-up after
9 months. The rate of clear corneas started at the same
level with both treatment methods but dropped sharply
in the Dresden protocol group. However, after 3 years,
both groups returned to a similar level (42% Dresden,
47.6% accelerated), although considerably fewer eyes in
the accelerated group could be followed-up for that
period (21 vs. 81 eyes). Nonetheless, most of the changes
and differences between the two groups were observed
in the first 12 months of the study, when both groups
had a comparable number of study subjects. For the
older protocol, a significant odds ratio of 0.273 was
found after 3 months and 0.152 after 6 months, indicat-
ing that a baseline clear cornea is again clear after treat-
ment. For the accelerated protocol, no significant
difference was determined. The variance could be ob-
served not only graphically, but also by statistical com-
parison, showing a significant difference after three and
6 months of treatment. The significant odds ratio was
0.417 and 0.232 for three and 6 months, respectively.
For striae, more fluctuation was observed in the pa-
tients treated with the conventional protocol. As with
clear corneas, the incidence of striae returned to a
comparable level after 3 years of follow-up (55.6%
Dresden, 52.4% accelerated). However, a larger fluctu-
ation occurred in the Dresden protocol group, as the
maximum rate of this feature increased to 67%, com-
pared with a maximum of 52.4% in the accelerated
group. For striae, we determined a significant odds
ratio of 4.0. after 6 months and 2.0 after 24 months
in the Dresden protocol group. The difference in the
odds ratio between both groups was significant after
3 months with a value of 2.0.
Obviously, the largest difference occurred for the de-
velopment of haze. This finding could be observed in
70.5% of patients after conventional treatment and in
46.9% of patients treated by the accelerated protocol.
When comparing the two protocols, the odds ratio was
2.0 but did not reach a significant level. The rate of haze
Table 4 Corneal measurements following the accelerated protocol
Finding pre-OP 3 M 6 M 9 M 12 M 24 M 36 M
Kmax [D] clear 51.2 53.06 52.84 53.6 50.85 50.9 50.1
Striae 56.6 56.6 56.7 56.5 58.7 57.1 57.8
p Striae-clear 0* 0.03* 0* 0.04* 0* 0* 0*
Haze 51.6 54.0 49.9 50.6 – 57.9 –
p Haze-clear 0.83 0.63 0.73 0.71 – 0.23 –
Kmf [D] clear 44.8 45.5 45.3 45.3 44.8 45.3 44
Striae 47.1 47.4 48.1 47.3 48.3 48 47.9
p Striae-clear 0* 0.05* 0.01* 0.15 0* 0* 0*
Haze 44.3 45.7 45.6 46.1 – 48.1 –
p Haze-clear 0.39 0.99 0.96 0.94 – 0.29 –
Pachymetry [μm] clear 472 461.3 461.5 466 480.5 474 453
Striae 455 451.9 443.5 465 461 457 443
p Striae-clear 0* 0.16 0.03* 0.59 0.02* 0.05* 0.81
Haze 483 458.8 440 409 – 479 –
p Haze-clear 0.84 0.65 0.08 0.2 – 0.79 –
Incidences [number of eyes] clear 75 61 40 22 20 32 10
Striae 69 59 44 27 25 29 11
Haze 3 61 7 1 0 1 0
Eyes 148 130 85 53 49 58 21
Corneal measurements (accelerated treatment, median) obtained during follow-up and concerning. M months, Kmax maximum K reading in keratometry measure-
ment, D dioptres, Kmf average keratometry reading of front cornea, corneal findings and incidences, *=statistical significant difference
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in our group is higher than that reported in other publi-
cations [30]. This might be because we additionally
follow-up our patients for a few days post-operatively
and not at longer intervals as in other studies. Further-
more, clinical findings are documented by an experi-
enced observer (WJM) based on subjective grading.
Tables 3 and 4 indicate that corneal measurement
values in Pentacam analyses differ between the treat-
ment protocols, when certain clinical findings are
present. Differences in measurement values occurred
more in the accelerated groups, if one or more corneal
findings were present. However, this trend could be ob-
served even pre-operatively. A more progressed kerato-
conus is known to show striae as a clinical sign. The
reason for the detection of a significant difference be-
tween clear corneas and those with striae might be that
when the accelerated protocol was introduced, more
confidence in CXL existed and treatment was initiated
earlier. However, no significant difference between the
Kmax values of the two treatment groups was seen be-
fore surgery.
The nature of this study, namely it being retrospective,
is a limitation of this investigation, as are the high num-
bers of patients who were lost to follow-up. One reason
is probably that some patients decided to be followed-up
by their local ophthalmologists; this might save them a
significant amount of time as most patients are of a
working age. The imbalance of patient numbers, in par-
ticular towards the end of the study, makes comparisons,
especially for the 3-year follow-up, difficult, because 81
eyes are still followed-up in the conventional CXL treat-
ment group and only 21 eyes in the accelerated protocol.
This is probably mostly attributable to the novelty of the
accelerated protocol, which was introduced in 2013 into
our hospital. To show long-term results in the present
report, we nevertheless decided to include the three-year
figures.
Conclusion
In conclusion, we can confirm that accelerated CXL is
as safe as CXL by using Dresden protocol, despite the
observation of fewer changes in corneal clinical findings.
As new protocols emerge (e.g. pulsed CXL, topoguided/
mosaic-CXL), further studies need to be conducted to
evaluate their effects on the cornea.
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